Trials / Completed
CompletedNCT03155243
Impact of Humira® Therapy on Ocular Inflammation, Selected Health Care Resource Utilization and Patient Reported Outcomes in Patients With Active Non-infectious Intermediate, Posterior and Panuveitis in Routine Clinical Practice
Impact of Humira® Therapy on Ocular Inflammation, Selected Health Care Resource Utilization and Patient Reported Outcomes in Patients With Active Non-infectious Intermediate, Posterior and Panuveitis in Routine Clinical Practice -HOPE
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 155 (actual)
- Sponsor
- AbbVie · Industry
- Sex
- All
- Age
- 18 Years – 99 Years
- Healthy volunteers
- Not accepted
Summary
This study aims at evaluating real life effectiveness of originator adalimumab (Humira®) participants with active non-infectious intermediate, posterior and panuveitis (NIIPPU) despite high-dose corticosteroid therapy; including effect on ocular inflammation, health-related quality of life, health resource utilization, work ability and medication burden, as well as describe the characteristics of NIIPPU participants treated with Humira® in the real-life setting.
Conditions
Timeline
- Start date
- 2017-06-20
- Primary completion
- 2020-02-24
- Completion
- 2020-02-24
- First posted
- 2017-05-16
- Last updated
- 2021-02-11
Locations
28 sites across 12 countries: Austria, Colombia, Czechia, Germany, Greece, Hungary, Ireland, Israel, Kuwait, Lebanon, Switzerland, United Arab Emirates
Source: ClinicalTrials.gov record NCT03155243. Inclusion in this directory is not an endorsement.